menu
    • menu
    [{"orgOrder":0,"company":"Minakem (formerly Delmar Chemicals)","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Private Placement","leadProduct":"Dianhydrogalactitol","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Minakem (formerly Delmar Chemicals)","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Minakem (formerly Delmar Chemicals) \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minakem (formerly Delmar Chemicals) \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Minakem

    Menu

    Minakem

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    Key Products KEY PRODUCTS

    SERVICES

    Key Services KEY SERVICES

    EXCIPIENTS

    Key Excipients KEY EXCIPIENTS

    EXCIPIENTS BY INGREDIENTS

    EXCIPIENTS BY APPLICATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Minakem (formerly Delmar Chemicals)

    Canada
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothMinakem is manufacturing small molecules APIs including corticosteroids

    Lead Product(s) : Dianhydrogalactitol

    Therapeutic Area : Oncology

    Study Phase : Phase III

    Sponsor : Undisclosed

    Deal Size : $19.6 million

    Deal Type : Private Placement

    DEALS_DEV arrow-down

    DelMar Announces $19.6 Million Private Placement Priced at-the-Market

    Details : Company intends to use the net proceeds from the offering for the previously announced registration study for VAL-083 in newly diagnosed and recurrent glioblastoma multiforme, the 15-patient REM-001 confirmatory lead-in study and for working capital.

    Product Name : VAL-083

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    August 18, 2020

    Lead Product(s) : Dianhydrogalactitol

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Sponsor : Undisclosed

    Deal Size : $19.6 million

    Deal Type : Private Placement

    Minakem Delmar

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth